Paliperidone for irritability in adolescents and young adults with autistic disorder

Kimberly A. Stigler, Jennifer E. Mullett, Craig A. Erickson, David J. Posey, Christopher J. McDougle

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Rationale Individuals with autistic disorder (autism) frequently exhibit significant irritability marked by severe tantrums, aggression, and self-injury. Despite advances in the treatment of this symptom domain in autism, there remains an ongoing need for more effective and better tolerated pharmacotherapies. Objectives The aim of this study is to determine the effectiveness and tolerability of paliperidone for irritability in autism. Methods This is a prospective, 8-week open-label study of paliperidone in 25 adolescents and young adults with autism. Primary outcome measures included the Clinical Global Impressions-Improvement (CGI-I) Scale and the Irritability subscale of the Aberrant Behavior Checklist (ABC-I). Concomitant medications (except antipsychotics) were permitted if dosages were stable for ≥2 months. Results Twenty-one (84 %) of 25 subjects ages 12-21 years (mean 15.3 years) responded to paliperidone, based on a CGII Scale score of 1 or 2 (very much or much improved) and ≥25 % improvement on the ABC-I. The mean final dosage of paliperidone was 7.1 mg/day (range 3-12 mg/day). Two subjects discontinued paliperidone prior to study completion (moderate sedation, n01; nonresponse, n01). Mild-tomoderate extrapyramidal symptoms were recorded in four subjects. A mean weight gain of 2.2 ± 2.6 kg (range -3.6 to +7.9 kg) was recorded. Mean age- and sex-normed body mass index increased from 23.6 to 24.2 (p≤ 0.001). Mean serum prolactin increased from 5.3 to 41.4 ng/mL (p≤0.0001). Conclusions Paliperidone treatment was associated with significant improvement in irritability and was generally well tolerated. Larger scale, placebo-controlled studies are needed to elucidate the efficacy and tolerability of paliperidone in this population.

Original languageEnglish
Pages (from-to)237-245
Number of pages9
JournalPsychopharmacology
Volume223
Issue number2
DOIs
StatePublished - Sep 2012

Fingerprint

Autistic Disorder
Young Adult
Conscious Sedation
Paliperidone Palmitate
Checklist
Aggression
Prolactin
Antipsychotic Agents
Weight Gain
Body Mass Index
Placebos
Outcome Assessment (Health Care)
Drug Therapy
Wounds and Injuries
Therapeutics
Serum
Population

Keywords

  • Autistic disorder
  • Irritability
  • Paliperidone

ASJC Scopus subject areas

  • Pharmacology

Cite this

Stigler, K. A., Mullett, J. E., Erickson, C. A., Posey, D. J., & McDougle, C. J. (2012). Paliperidone for irritability in adolescents and young adults with autistic disorder. Psychopharmacology, 223(2), 237-245. https://doi.org/10.1007/s00213-012-2711-3

Paliperidone for irritability in adolescents and young adults with autistic disorder. / Stigler, Kimberly A.; Mullett, Jennifer E.; Erickson, Craig A.; Posey, David J.; McDougle, Christopher J.

In: Psychopharmacology, Vol. 223, No. 2, 09.2012, p. 237-245.

Research output: Contribution to journalArticle

Stigler, KA, Mullett, JE, Erickson, CA, Posey, DJ & McDougle, CJ 2012, 'Paliperidone for irritability in adolescents and young adults with autistic disorder', Psychopharmacology, vol. 223, no. 2, pp. 237-245. https://doi.org/10.1007/s00213-012-2711-3
Stigler, Kimberly A. ; Mullett, Jennifer E. ; Erickson, Craig A. ; Posey, David J. ; McDougle, Christopher J. / Paliperidone for irritability in adolescents and young adults with autistic disorder. In: Psychopharmacology. 2012 ; Vol. 223, No. 2. pp. 237-245.
@article{9162e49979344002ba277509994771e3,
title = "Paliperidone for irritability in adolescents and young adults with autistic disorder",
abstract = "Rationale Individuals with autistic disorder (autism) frequently exhibit significant irritability marked by severe tantrums, aggression, and self-injury. Despite advances in the treatment of this symptom domain in autism, there remains an ongoing need for more effective and better tolerated pharmacotherapies. Objectives The aim of this study is to determine the effectiveness and tolerability of paliperidone for irritability in autism. Methods This is a prospective, 8-week open-label study of paliperidone in 25 adolescents and young adults with autism. Primary outcome measures included the Clinical Global Impressions-Improvement (CGI-I) Scale and the Irritability subscale of the Aberrant Behavior Checklist (ABC-I). Concomitant medications (except antipsychotics) were permitted if dosages were stable for ≥2 months. Results Twenty-one (84 {\%}) of 25 subjects ages 12-21 years (mean 15.3 years) responded to paliperidone, based on a CGII Scale score of 1 or 2 (very much or much improved) and ≥25 {\%} improvement on the ABC-I. The mean final dosage of paliperidone was 7.1 mg/day (range 3-12 mg/day). Two subjects discontinued paliperidone prior to study completion (moderate sedation, n01; nonresponse, n01). Mild-tomoderate extrapyramidal symptoms were recorded in four subjects. A mean weight gain of 2.2 ± 2.6 kg (range -3.6 to +7.9 kg) was recorded. Mean age- and sex-normed body mass index increased from 23.6 to 24.2 (p≤ 0.001). Mean serum prolactin increased from 5.3 to 41.4 ng/mL (p≤0.0001). Conclusions Paliperidone treatment was associated with significant improvement in irritability and was generally well tolerated. Larger scale, placebo-controlled studies are needed to elucidate the efficacy and tolerability of paliperidone in this population.",
keywords = "Autistic disorder, Irritability, Paliperidone",
author = "Stigler, {Kimberly A.} and Mullett, {Jennifer E.} and Erickson, {Craig A.} and Posey, {David J.} and McDougle, {Christopher J.}",
year = "2012",
month = "9",
doi = "10.1007/s00213-012-2711-3",
language = "English",
volume = "223",
pages = "237--245",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Paliperidone for irritability in adolescents and young adults with autistic disorder

AU - Stigler, Kimberly A.

AU - Mullett, Jennifer E.

AU - Erickson, Craig A.

AU - Posey, David J.

AU - McDougle, Christopher J.

PY - 2012/9

Y1 - 2012/9

N2 - Rationale Individuals with autistic disorder (autism) frequently exhibit significant irritability marked by severe tantrums, aggression, and self-injury. Despite advances in the treatment of this symptom domain in autism, there remains an ongoing need for more effective and better tolerated pharmacotherapies. Objectives The aim of this study is to determine the effectiveness and tolerability of paliperidone for irritability in autism. Methods This is a prospective, 8-week open-label study of paliperidone in 25 adolescents and young adults with autism. Primary outcome measures included the Clinical Global Impressions-Improvement (CGI-I) Scale and the Irritability subscale of the Aberrant Behavior Checklist (ABC-I). Concomitant medications (except antipsychotics) were permitted if dosages were stable for ≥2 months. Results Twenty-one (84 %) of 25 subjects ages 12-21 years (mean 15.3 years) responded to paliperidone, based on a CGII Scale score of 1 or 2 (very much or much improved) and ≥25 % improvement on the ABC-I. The mean final dosage of paliperidone was 7.1 mg/day (range 3-12 mg/day). Two subjects discontinued paliperidone prior to study completion (moderate sedation, n01; nonresponse, n01). Mild-tomoderate extrapyramidal symptoms were recorded in four subjects. A mean weight gain of 2.2 ± 2.6 kg (range -3.6 to +7.9 kg) was recorded. Mean age- and sex-normed body mass index increased from 23.6 to 24.2 (p≤ 0.001). Mean serum prolactin increased from 5.3 to 41.4 ng/mL (p≤0.0001). Conclusions Paliperidone treatment was associated with significant improvement in irritability and was generally well tolerated. Larger scale, placebo-controlled studies are needed to elucidate the efficacy and tolerability of paliperidone in this population.

AB - Rationale Individuals with autistic disorder (autism) frequently exhibit significant irritability marked by severe tantrums, aggression, and self-injury. Despite advances in the treatment of this symptom domain in autism, there remains an ongoing need for more effective and better tolerated pharmacotherapies. Objectives The aim of this study is to determine the effectiveness and tolerability of paliperidone for irritability in autism. Methods This is a prospective, 8-week open-label study of paliperidone in 25 adolescents and young adults with autism. Primary outcome measures included the Clinical Global Impressions-Improvement (CGI-I) Scale and the Irritability subscale of the Aberrant Behavior Checklist (ABC-I). Concomitant medications (except antipsychotics) were permitted if dosages were stable for ≥2 months. Results Twenty-one (84 %) of 25 subjects ages 12-21 years (mean 15.3 years) responded to paliperidone, based on a CGII Scale score of 1 or 2 (very much or much improved) and ≥25 % improvement on the ABC-I. The mean final dosage of paliperidone was 7.1 mg/day (range 3-12 mg/day). Two subjects discontinued paliperidone prior to study completion (moderate sedation, n01; nonresponse, n01). Mild-tomoderate extrapyramidal symptoms were recorded in four subjects. A mean weight gain of 2.2 ± 2.6 kg (range -3.6 to +7.9 kg) was recorded. Mean age- and sex-normed body mass index increased from 23.6 to 24.2 (p≤ 0.001). Mean serum prolactin increased from 5.3 to 41.4 ng/mL (p≤0.0001). Conclusions Paliperidone treatment was associated with significant improvement in irritability and was generally well tolerated. Larger scale, placebo-controlled studies are needed to elucidate the efficacy and tolerability of paliperidone in this population.

KW - Autistic disorder

KW - Irritability

KW - Paliperidone

UR - http://www.scopus.com/inward/record.url?scp=84866737066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866737066&partnerID=8YFLogxK

U2 - 10.1007/s00213-012-2711-3

DO - 10.1007/s00213-012-2711-3

M3 - Article

C2 - 22549762

AN - SCOPUS:84866737066

VL - 223

SP - 237

EP - 245

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 2

ER -